Pexiganan vs Ramoplanin — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Pexiganan (MSI-78) is a synthetic analog of magainin-2, optimized for enhanced broad-spectrum antimicrobial activity and reduced hemolytic toxicity. It was developed by Magainin Pharmaceuticals (later Genaera) as a topical treatment for mildly infected diabetic foot ulcers....
Calculate Pexiganan dose →Ramoplanin is a glycodepsipeptide antibiotic produced by Actinoplanes sp. ATCC 33076 with potent activity against gram-positive bacteria....
Calculate Ramoplanin dose →| Parameter | Pexiganan | Ramoplanin |
|---|---|---|
| Category | Antimicrobial Peptide | Antimicrobial Peptide |
| Research | Phase 3 (Failed 1999) | Phase 3 (Discontinued) |
| Half-Life | Hours (topical) | Short (gut lumen) |
| Typical Dose | 0.8% cream topically | 200 mg twice daily |
| Frequency | Twice daily | Twice daily |
| Route | Topical cream | Oral (non-absorbed) |
| FDA Status | Not approved (failed Phase 3) | Not approved (Phase 3 discontinued) |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.